TY - JOUR
T1 - HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy
AU - Moretti, Sonia
AU - Cafaro, Aurelio
AU - Tripiciano, Antonella
AU - Picconi, Orietta
AU - Buttò, Stefano
AU - Ensoli, Fabrizio
AU - Sgadari, Cecilia
AU - Monini, Paolo
AU - Ensoli, Barbara
N1 - Funding Information:
A reviewer on this manuscript has disclosed that they have received travel grants from Gilead, Merck, Gilead, Bristol and Pfizer; payment for lectures from Merck, Gilead, Bristol and Abbvie; consulting fees from Angelini SpA. and research funding from Gilead. All other peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.
Publisher Copyright:
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/1/2
Y1 - 2020/1/2
N2 - Introduction: Although successful at suppressing HIV replication, combination antiretroviral therapy (cART) only partially restores immune functions and fails to reduce the latent HIV reservoir, thus requiring novel interventions for its intensification. Areas covered: Here are reviewed therapeutic vaccine candidates that are being developed to this goal. Among them, the Tat vaccine has been shown to promote immune restoration, including CD4+ T-cell recovery in low immunological responders, and to reduce the virus reservoirs well beyond what achieved with long-term suppressive cART. Expert opinion: The authors propose the Tat vaccine as a promising vaccine candidate for cART intensification toward HIV reservoirs depletion, functional cure, and eradication strategies, suggesting that targeting a key protein in the virus life cycle is pivotal to success.
AB - Introduction: Although successful at suppressing HIV replication, combination antiretroviral therapy (cART) only partially restores immune functions and fails to reduce the latent HIV reservoir, thus requiring novel interventions for its intensification. Areas covered: Here are reviewed therapeutic vaccine candidates that are being developed to this goal. Among them, the Tat vaccine has been shown to promote immune restoration, including CD4+ T-cell recovery in low immunological responders, and to reduce the virus reservoirs well beyond what achieved with long-term suppressive cART. Expert opinion: The authors propose the Tat vaccine as a promising vaccine candidate for cART intensification toward HIV reservoirs depletion, functional cure, and eradication strategies, suggesting that targeting a key protein in the virus life cycle is pivotal to success.
KW - anti-Tat antibodies
KW - cART intensification
KW - clinical trials
KW - functional cure
KW - HIV reservoir
KW - HIV-1 Tat
KW - HIV-1 therapeutic vaccine
KW - immune system restoration
KW - immunotherapy
KW - proviral DNA
UR - http://www.scopus.com/inward/record.url?scp=85078234180&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078234180&partnerID=8YFLogxK
U2 - 10.1080/14760584.2020.1712199
DO - 10.1080/14760584.2020.1712199
M3 - Review article
C2 - 31957513
AN - SCOPUS:85078234180
VL - 19
SP - 71
EP - 84
JO - Expert Review of Vaccines
JF - Expert Review of Vaccines
SN - 1476-0584
IS - 1
ER -